Compare · CBUS vs NITO
CBUS vs NITO
Side-by-side comparison of Cibus Inc. (CBUS) and N2OFF Inc. (NITO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and NITO operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS carries a market cap of $103.2M.
- Over the past year, CBUS is down 10.1% and NITO is down 64.1% - CBUS leads by 54.0 points.
- CBUS has more recent analyst coverage (4 ratings vs 0 for NITO).
PerformanceCBUS-45.93%NITO-64.08%
2026-07-14+0.00%2026-10-30
- Company
- Cibus Inc.
- N2OFF Inc.
- Price
- $1.29-2.26%
- $1.25+32.98%
- Market cap
- $103.2M
- -
- 1M return
- -21.04%
- -15.54%
- 1Y return
- -10.07%
- -64.08%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 0
Latest CBUS
- Cibus and Crystal Crop Protection Team Up to Improve India’s Mustard Crop
- SEC Form 10-Q filed by Cibus Inc.
- Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cibus Reports Second Quarter Financial Results and Provides Business Update
- Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest NITO
- SEC Form PRE 14A filed by N2OFF Inc.
- N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- N2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
- N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
- MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases
- Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)
- Chief Financial Officer Barda Lital was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions